Cancer Cell,
Journal Year:
2024,
Volume and Issue:
42(2), P. 180 - 197
Published: Feb. 1, 2024
The
past
decade
has
witnessed
significant
advances
in
the
systemic
treatment
of
advanced
hepatocellular
carcinoma
(HCC).
Nevertheless,
newly
developed
strategies
have
not
achieved
universal
success
and
HCC
patients
frequently
exhibit
therapeutic
resistance
to
these
therapies.
Precision
represents
a
paradigm
shift
cancer
recent
years.
This
approach
utilizes
unique
molecular
characteristics
individual
patient
personalize
modalities,
aiming
maximize
efficacy
while
minimizing
side
effects.
Although
precision
shown
multiple
types,
its
application
remains
infancy.
In
this
review,
we
discuss
key
aspects
HCC,
including
biomarkers,
classifications,
heterogeneity
tumor
microenvironment.
We
also
propose
future
directions,
ranging
from
revolutionizing
current
methodologies
personalizing
therapy
through
functional
assays,
which
will
accelerate
next
phase
advancements
area.
Nature Medicine,
Journal Year:
2024,
Volume and Issue:
30(3), P. 785 - 796
Published: Feb. 16, 2024
Abstract
Multiple
clinical
trials
targeting
the
gut
microbiome
are
being
conducted
to
optimize
treatment
outcomes
for
immune
checkpoint
blockade
(ICB).
To
improve
success
of
these
interventions,
understanding
changes
during
ICB
is
urgently
needed.
Here
through
longitudinal
profiling
175
patients
treated
with
advanced
melanoma,
we
show
that
several
microbial
species-level
genome
bins
(SGBs)
and
pathways
exhibit
distinct
patterns
from
baseline
in
achieving
progression-free
survival
(PFS)
12
months
or
longer
(PFS
≥12)
versus
PFS
shorter
than
<12).
Out
99
SGBs
could
discriminate
between
two
groups,
20
were
differentially
abundant
only
at
baseline,
while
42
after
initiation.
We
identify
five
four
had
consistently
higher
abundances
≥12
<12
months,
respectively.
Constructing
a
log
ratio
SGBs,
find
an
association
overall
survival.
Finally,
different
dynamics
contexts
including
type
regimen,
development
immune-related
adverse
events
concomitant
medication
use.
Insights
into
host
factors
regimens
will
be
critical
guiding
rational
microbiome-targeted
therapies
aimed
enhancing
efficacy.
Cell,
Journal Year:
2024,
Volume and Issue:
187(13), P. 3373 - 3389.e16
Published: June 1, 2024
The
gut
microbiota
influences
the
clinical
responses
of
cancer
patients
to
immunecheckpoint
inhibitors
(ICIs).
However,
there
is
no
consensus
definition
detrimental
dysbiosis.
Based
on
metagenomics
(MG)
sequencing
245
non-small
cell
lung
(NSCLC)
patient
feces,
we
constructed
species-level
co-abundance
networks
that
were
clustered
into
species-interacting
groups
(SIGs)
correlating
with
overall
survival.
Thirty-seven
and
forty-five
MG
species
(MGSs)
associated
resistance
(SIG1)
response
(SIG2)
ICIs,
respectively.
When
combined
quantification
Akkermansia
species,
this
procedure
allowed
a
person-based
calculation
topological
score
(TOPOSCORE)
was
validated
in
an
additional
254
NSCLC
216
genitourinary
patients.
Finally,
TOPOSCORE
translated
21-bacterial
probe
set-based
qPCR
scoring
prospective
cohort
as
well
colorectal
melanoma
This
approach
could
represent
dynamic
diagnosis
tool
for
intestinal
dysbiosis
guide
personalized
microbiota-centered
interventions.
Molecular Cancer,
Journal Year:
2024,
Volume and Issue:
23(1)
Published: May 18, 2024
Abstract
Aging
and
cancer
exhibit
apparent
links
that
we
will
examine
in
this
review.
The
null
hypothesis
aging
coincide
because
both
are
driven
by
time,
irrespective
of
the
precise
causes,
can
be
confronted
with
idea
share
common
mechanistic
grounds
referred
to
as
‘hallmarks’.
Indeed,
several
hallmarks
also
contribute
carcinogenesis
tumor
progression,
but
some
molecular
cellular
characteristics
may
reduce
probability
developing
lethal
cancer,
perhaps
explaining
why
very
old
age
(>
90
years)
is
accompanied
a
reduced
incidence
neoplastic
diseases.
We
discuss
possibility
process
itself
causes
meaning
time-dependent
degradation
supracellular
functions
accompanies
produces
byproduct
or
‘age-associated
disease’.
Conversely,
its
treatment
erode
health
drive
process,
has
dramatically
been
documented
for
survivors
diagnosed
during
childhood,
adolescence,
young
adulthood.
conclude
connected
superior
including
endogenous
lifestyle
factors,
well
bidirectional
crosstalk,
together
render
not
only
risk
factor
an
important
parameter
must
considered
therapeutic
decisions.
Nature Medicine,
Journal Year:
2024,
Volume and Issue:
30(3), P. 797 - 809
Published: March 1, 2024
Abstract
Immune
checkpoint
blockade
(ICB)
targeting
programmed
cell
death
protein
1
(PD-1)
and
cytotoxic
T
lymphocyte
4
(CTLA-4)
can
induce
remarkable,
yet
unpredictable,
responses
across
a
variety
of
cancers.
Studies
suggest
that
there
is
relationship
between
cancer
patient’s
gut
microbiota
composition
clinical
response
to
ICB;
however,
defining
microbiome-based
biomarkers
generalize
cohorts
has
been
challenging.
This
may
relate
previous
efforts
quantifying
species
(or
higher
taxonomic
rank)
abundances,
whereas
microbial
functions
are
often
strain
specific.
Here,
we
performed
deep
shotgun
metagenomic
sequencing
baseline
fecal
samples
from
unique,
richly
annotated
phase
2
trial
cohort
patients
with
diverse
rare
cancers
treated
combination
ICB
(
n
=
106
discovery
cohort).
We
demonstrate
strain-resolved
abundances
improve
machine
learning
predictions
12-month
progression-free
survival
relative
models
built
using
species-rank
quantifications
or
comprehensive
pretreatment
factors.
Through
meta-analysis
metagenomes
further
six
comparable
studies
364
validation
cohort),
found
cross-cancer
(and
cross-country)
validity
strain–response
signatures,
but
only
when
the
training
test
used
concordant
regimens
(anti-PD-1
monotherapy
anti-PD-1
plus
anti-CTLA-4).
suggests
future
development
microbiome
diagnostics
therapeutics
should
be
tailored
according
treatment
regimen
rather
than
type.
Cancer Cell,
Journal Year:
2023,
Volume and Issue:
42(1), P. 16 - 34
Published: Dec. 28, 2023
Over
the
last
decade,
composition
of
gut
microbiota
has
been
found
to
correlate
with
outcomes
cancer
patients
treated
immunotherapy.
Accumulating
evidence
points
various
mechanisms
by
which
intestinal
bacteria
act
on
distal
tumors
and
how
harness
this
complex
ecosystem
circumvent
primary
resistance
immune
checkpoint
inhibitors.
Here,
we
review
state
field
in
context
melanoma,
recent
breakthroughs
defining
microbial
modes
action,
modulate
enhance
response
The
host-microbe
interaction
may
be
deciphered
use
"omics"
technologies,
will
guide
patient
stratification
development
microbiota-centered
interventions.
Efforts
needed
advance
current
gaps
knowledge
are
also
discussed.
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(20), P. 15321 - 15321
Published: Oct. 18, 2023
Gastric
cancer
presents
substantial
management
challenges,
and
the
advent
of
immunotherapy
has
ignited
renewed
hope
among
patients.
Nevertheless,
a
significant
proportion
patients
do
not
respond
to
immunotherapy,
adverse
events
associated
with
also
occur
on
occasion,
underscoring
imperative
identify
suitable
candidates
for
treatment.
Several
biomarkers,
including
programmed
death
ligand-1
expression,
tumor
mutation
burden,
mismatch
repair
status,
Epstein–Barr
Virus
infection,
circulating
DNA,
tumor-infiltrating
lymphocytes,
have
demonstrated
potential
in
predicting
effectiveness
gastric
cancer.
However,
quest
optimal
predictive
biomarker
remains
challenging,
as
each
carries
its
own
limitations.
Recently,
multi-omics
technologies
emerged
promising
platforms
discovering
novel
biomarkers
that
may
help
selecting
likely
immunotherapy.
The
identification
reliable
holds
promise
enhancing
patient
selection
improving
treatment
outcomes.
In
this
review,
we
aim
provide
an
overview
clinically
established
Additionally,
introduce
newly
reported
based
studies
context
thereby
contributing
ongoing
efforts
refine
stratification
strategies.
Cell Reports Medicine,
Journal Year:
2024,
Volume and Issue:
5(4), P. 101487 - 101487
Published: March 27, 2024
The
gut
microbiota
influences
anti-tumor
immunity
and
can
induce
or
inhibit
response
to
immune
checkpoint
inhibitors
(ICIs).
Therefore,
microbiome
features
are
being
studied
as
predictive/prognostic
biomarkers
of
patient
ICIs,
microbiome-based
interventions
attractive
adjuvant
treatments
in
combination
with
ICIs.
Specific
gut-resident
bacteria
influence
the
effectiveness
immunotherapy;
however,
mechanism
action
on
how
these
affect
ICIs
is
not
fully
understood.
Nevertheless,
early
bacterial-based
therapeutic
strategies
have
demonstrated
that
targeting
through
various
methods
enhance
resulting
improved
clinical
responses
patients
a
diverse
range
cancers.
understanding
microbiota-driven
mechanisms
immunotherapy
augment
success
interventions,
particularly
treatment-refractory
Biomarker Research,
Journal Year:
2024,
Volume and Issue:
12(1)
Published: June 3, 2024
Abstract
Background
Accumulating
evidence
suggests
that
the
gut
microbiota
and
metabolites
can
modulate
tumor
responses
to
immunotherapy;
however,
limited
data
has
been
reported
on
biliary
tract
cancer
(BTC).
This
study
used
metagenomics
metabolomics
identify
characteristics
of
microbiome
in
immunotherapy-treated
BTC
their
potential
as
prognostic
predictive
biomarkers.
Methods
prospective
cohort
enrolled
88
patients
with
who
received
PD-1/PD-L1
inhibitors
from
November
2018
May
2022.
The
significantly
enriched
different
immunotherapy
response
groups
were
identified
through
LC-MS/MS.
Associations
between
metabolites,
clinical
factors,
factors
explored.
Results
Significantly
bacteria
both
durable
benefit
(DCB)
non-durable
(NDB)
groups.
Of
these,
20
two
associated
survival.
Alistipes
positively
correlated
survival,
while
Bacilli
,
Lactobacillales
Pyrrolidine
negatively
Predictive
models
based
six
bacteria,
four
combination
three
could
all
discriminated
DCB
NDB
high
accuracy.
Beta
diversity
was
different,
composition
varied
differences
use
immunotherapy.
Conclusions
Patients
receiving
have
specific
alterations
interactions
metabolites.
These
findings
suggest
are
biomarkers
for
outcomes
anti-PD-1/PD-L1-treated
BTC.
